Trials / Terminated
TerminatedNCT01643603
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
Phase I Study of Dasatinib in Recipients of Allogeneic Stem Cell Transplantation for Hematologic Malignancies.
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Barbara Ann Karmanos Cancer Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study uses a drug called dasatinib to produce an anti-cancer effect called large granular lymphocyte cellular expansion. Large granular lymphocytes are blood cells known as natural killer cells that remove cancer cells. Researchers think that dasatinib may cause large granular lymphocyte expansion to happen in patients who have received a blood stem cell transplant (SCT) between 3 to 15 months after the SCT. In this research study, researchers want to find how well dasatinib can be tolerated, the best dose to take of dasatinib and how to estimate how often large granular lymphocytic cellular expansion happens at the best dose of dasatinib.
Detailed description
This is a phase I, dose-escalation study.
Conditions
- Non-Hodgkin's Lymphoma
- Hodgkin's Lymphoma
- Myeloid Leukemia
- Multiple Myeloma
- Myelodysplastic Syndrome
- Lymphoid Leukemia
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dasatinib | Patients receive dasatinib PO every day (QD) for 6 months. |
| OTHER | laboratory biomarker analysis | Correlative studies |
Timeline
- Start date
- 2012-05-01
- Primary completion
- 2018-10-09
- Completion
- 2018-10-09
- First posted
- 2012-07-18
- Last updated
- 2020-12-17
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01643603. Inclusion in this directory is not an endorsement.